Everolimus

Each film-coated tablet contains Everolimus……………………5mg.

Each film-coated tablet contains: Everolimus……………………10mg.

INDICATION:

LuciEver is a kinase inhibitor indicated for the treatment of:

• Postmenopausal women with advanced hormone receptor-positive, HER2- negative breast cancer in combination with exemestane after failure of treatment with letrozole or anastrozole.

• Adults with progressive neuroendocrine tumors of pancreatic origin (PNET) and adults with progressive, well-differentiated, non-functional neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin that are unresectable, locally advanced or metastatic.

• Adults with advanced renal cell carcinoma (RCC) after failure of treatment with sunitinib or sorafenib.

• Adults with renal angiomyolipoma and tuberous sclerosis complex (TSC), not requiring immediate surgery.

DOSAGE AND USE:

Breast Cancer: 10 mg orally once daily.

NET: 10 mg orally once daily.

RCC: 10 mg orally once daily.

TSC-Associated Renal Angiomyolipoma: 10 mg orally once daily.

STORAGE:

In a dry place and store at 20℃ to 25℃.

WARNING:

Keep medicine out of reach of Children. Do not administer LuciEver during Pregnancy and Lactation.

PLEASE SEE PACKAGE INSERT